[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sohag University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":574},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,366,0,25,[9,42,69,98,122,143,169,187,210,230,254,277,296,314,337,365,385,407,428,449,472,496,514,537,556],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053347","role-of-endoscopic-third-ventriculostomy-imanagement-of-hydrocephalus-in-pediatric-age-group-clinical-and-surgical-outcome-100053347",false,"NCT07694518","Role of Endoscopic Third Ventriculostomy Imanagement of Hydrocephalus in Pediatric Age Group; Clinical and Surgical Outcome","Role of Endoscopic Third Ventriculostomy in Management of Hydrocephalus in Pediatric Age Group; Clinical and Surgical Outcome","Inclusion Criteria:\n\n* cases hydrocephalus diagnosed by CT or MRI.in pediatric age group up to 18 years\n* Both sex (males and females) will be included.\n\nExclusion Criteria:\n\n* cases with hydrocephalus associated with csf infection or hemorrhage\n* Previously operated VP shunt or ETV .\n* Mult cystic hydrocephalus","ALL","6 Months","18 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","Endoscopic third ventriculostomy in cases of hydrocephalus provide less invasive and safe technique than ventriculoperitoneal Shunt also decrease complications of ventriculoperitoneal Shunt",[28],"Hydrocephalus","NOT_YET_RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-07-12",{"date":37,"type":22},"2026-12-24",{"name":39,"class":40},"Sohag University","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100053871","eating-behaviour-and-snack-consumption-patterns-among-children-with-adhd-100053871","NCT07690033","Eating Behaviour and Snack Consumption Patterns Among Children With ADHD","Eating Behaviour and Snack Consumption Patterns Among Children With Attention Deficit Hyperactivity Disorder","ADHD children","Inclusion Criteria:\n\n* Age 6-12 years.\n* Met the diagnostic criteria for ADHD by the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); and severity assessment by Conners Rating Scale (parent form)\n* For controls: negative ADHD assessment using DSM 5 clinical interview and Conners scale; no history of ADHD diagnosis\n\nExclusion Criteria:\n\n* ADHD symptoms due to other neurodevelopmental, psychotic, mood or organic disorders, or medication effects\n* Known neurological disease, severe chronic illness, or special diet that may alter intake\n* Use of psychotropic or appetite altering medications for ≥3 months\n* Refusal to participate",true,"6 Years","12 Years",{"count":54,"type":22},150,"OBSERVATIONAL","The goal of this observational study is to learn about the effect of eating behavior and snack consumption patterns among children with ADHD. The main question it aims to answer is:\n\nDoes snack consumption increase insidenc and severity of ADHD?? Participants will answer survey questions about their eating behavior and snack consumption patterns.",[58],"Attention Deficit and Hyperactivity Disorder (ADHD)",[60,61,62],"Snack consumption","Eating behaviour","ADHD",{"date":32,"type":33},{"date":65,"type":22},"2026-08-01",{"date":67,"type":22},"2027-02-01",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100644250","trial-of-management-of-chronic-tinnitus-by-sound-therapy-and-cognitive-behavioral-therapy-100644250","NCT07665385","Trial of Management of Chronic Tinnitus by Sound Therapy and Cognitive Behavioral Therapy","Efficacy of Sound Therapy, Cognitive Behavioral Therapy and Their Combination in Management of Chronic Tinnitus","Inclusion Criteria:\n\n* o Age: 18-65 years.\n\n  * Hearing level: Patients with normal hearing or mild to moderate sensorineural hearing loss (to ensure homogeneity of the sample) (National Institute for Health and Care Excellence, 2020)\n  * Complaint: patients with chronic subjective tinnitus (\\> 3 months).\n  * Psychological state: Patients with stable general and psychological condition.\n\nExclusion Criteria:\n\n* o Age: \\\u003C18, \\>65 years\n\n  * Hearing level: Patients with severe hearing loss not suitable for sound therapy\n  * Complaint: Objective tinnitus (vascular or muscular origin)\n  * Psychological state: Patients with active psychiatric disorders requiring immediate intervention.\n  * Active middle or external ear disease","18 Months","65 Months",{"count":79,"type":22},60,[25],"clinical trial: The main aim of this study is to compare the effectiveness of Cognitive Behavioral Therapy (CBT) and Sound Therapy, both individually and in combination, in the management of patients with chronic subjective tinnitus and to evaluate their impact on decreasing tinnitus severity, psychological wellbeing and quality of life.\n\nPatients will be randomly divided into three groups:\n\n* Group A: patients will receive Sound Therapy.\n* Group B: patients will receive Cognitive Behavioral Therapy (CBT).\n* Group C: patients will receive Combined CBT + Sound Therapy.",[83],"Chronic Subjective Tinnitus",[85,86,87,88,89],"Sound Therapy","Cognitive Behavioral Therapy","Chronic Tinnitus","Subjective Tinnitus","Tinnitus","2026-06-26",{"date":92,"type":33},"2026-06-30",{"date":94,"type":22},"2026-06-10",{"date":96,"type":22},"2026-12-10",{"name":39,"class":40},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":104,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":106,"studyType":55,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100645125","diagnostic-accuracy-of-multiparametric-dynamic-contrast-enhanced-magnetic-resonance-imaging-in-improving-detection-of-ultrasound-non-mass-breast-lesions-according-to-acr-bi-rads-v2025-100645125","NCT07679308","Diagnostic Accuracy of Multiparametric Dynamic Contrast Enhanced Magnetic Resonance Imaging in Improving Detection of Ultrasound Non-mass Breast Lesions According to ACR BI-RADS v2025","Inclusion Criteria:\n\n* • Female patients of any age presenting with non-mass breast lesions detected on MRI or conventional imaging.\n\n  * Patients who have both MRI and targeted Ultrasound examinations.\n\nExclusion Criteria:\n\n* • Patients presenting with typical distinct \"mass\" lesions (3D space-occupying lesions) without any non-mass components.\n\n  * Patients with absolute contraindications to MRI (e.g., cardiac pacemakers, severe claustrophobia, non-compatible metallic implants).\n  * Patients with contraindications to intravenous Gadolinium contrast media (e.g., severe renal impairment\u002Ffailure, pregnancy, known history of severe allergic reaction to gadolinium).","FEMALE",{"count":79,"type":22},"8 Months","this study aims To evaluate the diagnostic performance of Ultrasound (US) in correlation with Dynamic Magnetic Resonance Imaging (MRI) for the assessment, characterization, and evaluation of non-mass breast lesions.\n\nThe study will investigate whether DCE-MRI improves lesions detected by characterization and diagnostic accuracy when interpreted according to the ACR BIRADS v 2025 and so may help optimize breast imaging evaluation and support clinical decision making",[109],"Non Mass Breast Lesions",[111,112,113],"DCE Breast MRI","Non mass breast lesions","Breast US","2026-06-25",{"date":116,"type":33},"2026-07-01",{"date":118,"type":22},"2026-06",{"date":120,"type":22},"2028-01",{"name":39,"class":40},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":142,"locationsCount":41},"100577798","lipid-profile-in-diabetic-and-non-diabetic-ckd-patients-100577798","NCT06802978","Lipid Profile in Diabetic and Non Diabetic CKD Patients","Study of Lipid Profile in Diabetic and Non Diabetic Chronic Kidney Disease Patients in Sohag University Hospital","CKD","Inclusion Criteria:\n\n* Patients of chronic kidney disease (CKD) presenting to the Sohag University Hospital\n* Patients aged above 20 years of age.\n* All patients who have given consent for enrolling into the study.\n\nExclusion Criteria:\n\n* Patients aged 20 years of age or below.\n* Patients on lipid-lowering drugs.\n* Kidney transplanted patients.","21 Years",{"count":132,"type":22},200,"The goal of this observational study is to compare blood lipid (fat) levels in participants with chronic kidney disease (CKD) with diabetes and without diabetes and who over 20 years old.\n\nThe main question this study aims to answer is:\n\nDoes having diabetes make fat problems worse in people with chronic kidney disease (CKD), or is there no connection between them?\n\nResearchers will compare the blood lipid (fat) levels in people with chronic kidney disease (CKD) who have diabetes and those without diabetes to see if having diabetes makes lipid problems worse in CKD patients, or if there is no connection between diabetes and changes in lipid levels.\n\nParticipants will need to fast for 10 hours before undergoing this test. This means not eating any food or drinking anything except water.\n\nSamples will be taken and sent to laboratory immediately.",[135],"Chronic Kidney Disease Patients","RECRUITING","2026-06-23",{"date":90,"type":33},{"date":140,"type":33},"2025-02-01",{"date":118,"type":22},{"name":39,"class":40},{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":50,"sex":17,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":41},"100644432","phase-4-comparison-of-norepinehrine-versus-phenylepherine-infusion-for-prevention-of-post-spinal-hypotension-100644432","NCT07662408","Comparison of Norepinehrine Versus Phenylepherine Infusion for Prevention of Post-spinal Hypotension","Comparison of Norepinephrine Versus Phenylephrine Infusion for Prevention of Hypotension Due to Subarachnoid Block in Elderly Patients Undergoing Orthopedic Hip Surgery:A Prospective Randomized Trial","Inclusion Criteria:\n\n1. Age 60 years or older.\n2. ASA physical status I-III.\n3. Scheduled for elective hip surgery under subarachnoid block.\n4. Willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patient refusal.\n2. Contraindications to subarachnoid block.\n3. Severe cardiac disease.\n4. Uncontrolled hypertension.\n5. Allergy to study drugs.\n6. Emergency surgery.\n7. Monoamine oxidase inhibitor use.\n8. Cognitive impairment preventing informed consent.","60 Years","100 Years",{"count":153,"type":22},62,[155],"PHASE4","This prospective randomized double-blinded clinical trial aims to compare the efficacy and hemodynamic effects of prophylactic norepinephrine infusion versus phenylephrine infusion for prevention of spinal anesthesia-induced hypotension in elderly patients undergoing elective orthopedic hip surgery under subarachnoid block. Sixty-two patients aged 60 years or older will be randomly assigned into two equal groups to receive either norepinephrine infusion (8 µg\u002Fmin) or phenylephrine infusion (100 µg\u002Fmin) immediately after spinal anesthesia. The primary outcome is the mean heart rate during vasopressor infusion, while secondary outcomes include incidence of hypotension, severe hypotension, bradycardia, reactive hypertension, intraoperative fluid requirements, blood loss, transfusion requirements, and postoperative nausea and vomiting. Hemodynamic parameters will be monitored throughout surgery to evaluate the safety and effectiveness of both vasopressor strategies.",[158,159],"Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia","Orthopedic Hip Sugery in Eldely Patients",[161],"Norepinehrine versus phenylepherine infusion in management of post-spinal hypotension","2026-06-22",{"date":137,"type":33},{"date":165,"type":33},"2026-05-22",{"date":167,"type":22},"2027-03-14",{"name":39,"class":40},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":175,"targetDuration":177,"studyType":55,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100644023","assessing-knowledge-attitudes-trust-perceived-usefulness-and-barriers-to-using-artificial-intelligence-ai-in-gastroenterology-among-clinicians-and-patients-100644023","NCT07669025","Assessing Knowledge, Attitudes, Trust, Perceived Usefulness, and Barriers to Using Artificial Intelligence (AI) in Gastroenterology Among Clinicians and Patients","Inclusion Criteria:\n\n* Inclusion: -adult patients (≥18) attending GI clinics\u002Funits (inpatient or outpatient), cognitively able to complete questionnaire\n* Ability and willingness to sign the consent form\n\nExclusion Criteria:\n\n\\-",{"count":176,"type":22},100,"1 Day","-Introduction Innovative technological developments in medical image interpretation, diagnostic support, risk assessment for different illnesses, outcome prognostication, and, in some cases, treatment recommendation have all been made possible by artificial intelligence (AI) (Goh et. al., 2024).\n\nThe number of machine learning and artificial intelligence (AI) applications intended to enhance the caliber, efficacy, and efficiency of our clinical practice has increased dramatically in gastroenterology over the last 10 years.\n\n(Leggett et. al., 2024). Research on clinicians' acceptance and confidence in AI is becoming more and more crucial. This is due to the perception that healthcare workflow integration requires trust and acceptance of AI technology. Numerous studies have already shown that trust is one of the key factors influencing the use of AI in healthcare. Although there is growing clinical evidence of AI's accuracy in diagnosis and prognosis, more focus needs to be placed on physicians' level of acceptance and trust (Goh et. al., 2024).\n\nMore and more patients want to take a more active role in their medical care. As a result, patients' usage of digital health care tools-both online and mobile-has skyrocketed. As of right now, it's unclear if people use symptom checkers to enhance medical guidance or if they use them to replace in-person medical care by only seeking it when directed by AI (Meyer et. al., 2022).\n\n-Aim of the work: Primary: To measure knowledge, attitudes, trust, perceived usefulness, risk perception, and willingness to use AI in gastroenterology among (a) gastroenterology clinicians and (b) GI patients.\n\nSecondary:\n\n* To compare perspectives between clinicians and patients.\n* To explore factors associated with higher acceptance\u002Ftrust (age, prior AI exposure, digital literacy, years of practice).\n\nPatient and Methods:\n\nWe will conduct a cross-sectional study. We will conduct a survey using a structured questionnaire for two parallel target populations: clinicians and patients. The questionnaire will be created by a multidisciplinary team (authors) with expertise in patient experience, cognitive psychology, psychometrics, internal medicine, and diagnostic errors. Items in the questionnaire for testing risk perception, acceptance, and trust were adapted from various other studies \\[Hah et. al., 2021; Kader et. al., 2022; Goh et. al., 2024\\]\n\n* Participants\n\n  • Clinicians: - practicing gastroenterologists.\n* Ability and willingness to sign the consent form\n\n  • Patients: Inclusion: -adult patients (≥18) attending GI clinics\u002Funits (inpatient or outpatient), cognitively able to complete questionnaire\n* Ability and willingness to sign the consent form\n* Ethical consideration:\n\n  * The study will be approved by the local ethical committee.\n  * Informed consent will be obtained from patients.\n  * voluntary participation, confidentiality, right to withdraw. Questionnaire Development\n\n    1. Item generation: Based on literature and brief interviews with 8-10 clinicians and 8-10 patients.\n    2. Content validity: Review by a small expert panel (3-5 experts).\n    3. Cognitive testing: 10-15 participants from each group to ensure clarity and comprehension.\n    4. Pilot testing: Small sample (clinicians: \\~50; patients: \\~100) to refine items.\n* Questionnaire Domains\n\n  * Demographics\n  * Knowledge (self-rated ± short objective items)\n  * Attitudes toward AI in GI\n  * Trust \\& risk perception\n  * Perceived usefulness\n  * Willingness to use AI\n  * Barriers \\& facilitators\n* Data Collection:\n\nClinicians: Online survey (Google Forms). Patients: Paper or tablet-based survey in clinics. Consent obtained before participation; responses are anonymous.\n\nStatistical analysis:\n\nStatistical analysis will be conducted by SPSS. Parametric data will be expressed as mean ± standard deviation (SD), such as age, and will be evaluated statistically by means of Student t-test, while non-parametric data will be expressed as proportions, like male and female, and will be analyzed using chi-square. A p-value \\\u003C 0.05 will be considered significant.",[180],"AI and GIT","2026-06-21",{"date":114,"type":33},{"date":94,"type":22},{"date":185,"type":22},"2026-12-01",{"name":39,"class":40},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":41},"100630768","association-between-benign-paroxysmal-positional-vertigo-and-vitamin-d-deficiency--100630768","NCT07491965","Association Between Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency .","Association Between Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency ; Sohag University Hospital Experience.","Inclusion Criteria:\n\n* • Cases: Adults with a confirmed diagnosis of idiopathic BPPV based on positive Dix-Hallpike maneuver (nystagmus and vertigo lasting \\\u003C1 minute).\n\n  * Controls: Adults attending ENT clinic without history of vertigo or BPPV, confirmed by negative Dix-Hallpike test.\n\nExclusion Criteria:\n\n* Known causes of secondary vertigo (e.g., Meniere's disease, vestibular neuritis, central vertigo).\n\n  * Conditions affecting vitamin D metabolism (e.g., chronic kidney disease, malabsorption syndromes, hyperparathyroidism).\n  * Use of medications interfering with vitamin D levels (e.g., anticonvulsants, glucocorticoids) in the past 3 months.\n  * Pregnancy or lactation.\n  * Inability to provide consent.",{"count":195,"type":22},160,"Association between Benign Paroxysmal Positional Vertigo and Vitamin D deficiency",[198],"Benign Paroxysmal Positional Vertigo (BPPV)",[200,201],"Vitamin D deficiency","Benign Paroxysmal Positional Vertigo","2026-06-16",{"date":204,"type":33},"2026-06-18",{"date":206,"type":33},"2026-04-01",{"date":208,"type":22},"2026-10-01",{"name":39,"class":40},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":216,"maxAge":151,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100641732","divide-and-conquer-with-debulking-in-management-of-rocky-hard-cataract-100641732","NCT07654387","Divide and Conquer With Debulking in Management of Rocky Hard Cataract","Inclusion Criteria:\n\n* adults with rocky hard cataract\n\nExclusion Criteria:\n\n* patients with abnormal endothelial cell count.\n* patients with glaucoma.\n* patients with retinal problems.","40 Years",{"count":218,"type":22},50,[25],"The management of nucleus may be challenging in rocky hard cataracts. Hard cataracts are difficult to fragment, and the excessive energy required to emulsify the hard nucleus can result in complications such as corneal edema, inflammation, wound burn, posterior capsular rupture, and zonular dialysis. different surgical techniques are used for the management of hard cataracts, with their advantages and limitations. Divide and conquer with debulking is a new technique for management of rocky hard cataract.\n\nIn this research we assess its safety comparing it with standard divide and conquer technique.",[222],"Cataract Mature","2026-06-13",{"date":225,"type":33},"2026-06-17",{"date":116,"type":22},{"date":228,"type":22},"2026-11-01",{"name":39,"class":40},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":253},"100642788","risk-stratification-and-prognostic-value-of-right-ventricular-dysfunction-screening-using-transthoracic-echocardiography-in-acute-pulmonary-embolism-100642788","NCT07647497","Risk Stratification and Prognostic Value of Right Ventricular Dysfunction Screening Using Transthoracic Echocardiography in Acute Pulmonary Embolism","RVD-PE","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients with a confirmed diagnosis of acute pulmonary embolism.\n* Patients who underwent transthoracic echocardiographic assessment for right ventricular dysfunction.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients with incomplete clinical data.\n* Patients who did not undergo transthoracic echocardiography.",{"count":238,"type":22},112,"This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.",[241],"Pulmonary Embolism",[243,244,241,245],"Right Ventricular Dysfunction","Echocardiography","Risk Stratification",{"date":247,"type":33},"2026-06-15",{"date":249,"type":22},"2026-06-01",{"date":251,"type":22},"2026-11-30",{"name":39,"class":40},2,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":50,"sex":17,"minAge":19,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":263,"conditions":264,"keywords":269,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":41},"100641841","corneal-epithelial-thickness-mapping-by-anterior-segment-optical-coherence-tomography-in-patients-with-refractive-errors-100641841","NCT07647146","Corneal Epithelial Thickness Mapping by Anterior Segment Optical Coherence Tomography in Patients With Refractive Errors","Inclusion Criteria:\n\n* Age ≥ 18 years-\n* Patients diagnosed with myopia or hyperopia by refraction\n* Clear cornea with no evidence of corneal pathology\n* Ability to undergo reliable anterior segment imaging\n\nExclusion Criteria:\n\n* Inability to fixate or follow instructions\n* Family history of keratoconus\n* Glaucoma,Cataract\n* Previous ocular surgery including refractive surgery\n* Keratoconus or suspected corneal ectasia\n* Corneal opacities or scars\n* Contact lens wear within the last two weeks\n* Ocular trauma\n* systemic disease affecting the cornea ( Such as diabetes)","99 Years",{"count":262,"type":22},360,"This study evaluates corneal epithelial thickness using anterior segment optical coherence tomography (AS-OCT) in patients with refractive errors. It aims to assess the relationship between epithelial thickness patterns and different types of refractive errors.",[265,266,267,268],"Myopia","Hyperopia","Astigmatism","Emmetropia",[270],"Corneal epithelial thickness, AS-OCT, anterior segment optical coherence tomography, refractive errors, myopia, hyperopia, astigmatism, cornea","2026-06-09",{"date":247,"type":33},{"date":116,"type":22},{"date":275,"type":22},"2027-05-01",{"name":39,"class":40},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":41},"100642794","association-between-fatty-liver-and-inflammatory-biomarkers-100642794","NCT07636915","Association Between Fatty Liver and Inflammatory Biomarkers","Association Between Systemic Inflammatory Indexes and Metabolic Dysfunction Associated Steatotic Liver Disease","MASLD","Inclusion Criteria:\n\n* Patient older than 18 years were diagnosed with MASLD according to Delphi consensus criteria (Rinella et al., 2024). Attend to outpatient clinic of Tropical Medicine Department, Sohag University\n\nExclusion Criteria:\n\n1. Significant alcohol consumption (\\>20 g\u002Fday for females, \\>30 g\u002Fday for males).\n2. Other causes of chronic liver disease:\n\n   * Viral hepatitis (HBV, HCV)\n   * Autoimmune hepatitis.\n   * Wilson's disease.\n   * Hemochromatosis.\n   * Drug-induced liver injury.\n3. Active infection or acute inflammatory conditions.\n4. Malignancy.\n5. Pregnancy.",{"count":176,"type":22},"The newly adapted definition for MASLD includes evidence for hepatic steatosis by imaging or biopsy with at least one of the five cardiometabolic criteria; BMI ≥ 25 kg\u002Fm2 (≥23 kg\u002Fm2 in Asian) or waist circumference \\>94 cm in men, \\>80 cm in women, fasting serum glucose ≥ 126 mg\u002FdL or 2 hour post load glucose level ≥ 140 mg\u002FdL or HbA1c ≥ 5.7% or on treatment for type 2 diabetes mellitus ,blood pressure ≥130\u002F85 mmHg or antihypertensive treatment, plasma triglycerides ≥ 150 mg\u002FdL or on lipid lowering drug, and plasma HDL cholesterol \\\u003C 40 mg\u002FdL for men and \\\u003C 50 mg\u002FdL for women or on lipid lowering drug treatment (Rinella et al., 2024).\n\nThese metabolic factors contribute to disease progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma (Eid et al., 2024).\n\nWhile multiple biological pathways contribute to MASLD pathogenesis; systemic inflammation has emerged as a pivotal mechanism linking metabolic dysfunction to liver injury (Bessone et al., 2019)",[288],"Fatty Liver",[283],"2026-06-08",{"date":94,"type":33},{"date":116,"type":22},{"date":294,"type":22},"2027-03-01",{"name":39,"class":40},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":303,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100643825","depression-anxiety-and-sleep-in-parkinsons-disease-100643825","NCT07622303","Depression, Anxiety and Sleep in Parkinson's Disease","Assessment of Depression , Anxiety and Sleep Disorders in Patients With Idiopathic Parkinson's Disease","A-Inclusion Criteria:\n\n1. Patients diagnosed with idiopathic Parkinson's disease according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015).\n2. Age ≥ 50 years.\n3. Ability to understand and respond to questionnaires and rating scales.\n4. Ability and willingness to provide informed consent.\n\nB-Exclusion Criteria:\n\n1. Patients with atypical parkinsonism.\n2. Patients with a history of other major neurological disorders (e.g., stroke, Alzheimer's disease, multiple sclerosis).\n3. Patients with severe cognitive impairment or dementia that prevents reliable completion of rating scales.\n4. Patients with a current diagnosis of severe psychiatric disorders unrelated to 5-Parkinson's disease (e.g., schizophrenia, bipolar disorder).\n\n6-Patients with unstable medical conditions. 7-Patients unable or unwilling to provide informed consent.","50 Years",{"count":176,"type":22},"This study aims to assess the prevalence and severity of depression, anxiety, and sleep disorders among patients with idiopathic Parkinson's disease. The study will evaluate the relationship between neuropsychiatric symptoms and disease characteristics in order to improve early recognition and patient quality of life.",[307],"Parkinson's Disease","2026-06-05",{"date":271,"type":33},{"date":249,"type":22},{"date":312,"type":22},"2027-05-31",{"name":39,"class":40},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":41},"100643712","patterns-of-cardiac-arrhythmia-in-patients-with-chronic-kidney-disease-100643712","NCT07640919","Patterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease","Patterns of Cardiac Arrhythmia In Patients With Chronic Kidney Disease at Sohag University Hospitals","Arrhythmia","Inclusion Criteria:\n\n* Patients with CKD (no intercurrent illness or uremic symptoms, and not hospitalized in the previous 3 months) with renal replacement therapy on maintenance HD (three times\u002Fweek for at least three months) or without renal replacement therapy, aged 18 or above.\n\nExclusion Criteria:\n\n* Patients aged \\\u003C18 years old.\n* Patients on drugs that are known to prolong the QT interval (e.g., antibiotics as clarithromycin, antifungal as fluconazole, antiarrhythmics as amiodarone, antipsychotic as chlorpromazine)\n* Patients with structural heart diseases (e.g.,significant valvular lesions )\n* Patients with impaired left ventricular systolic functions (defined as EF\\\u003C 50%\n* Patients with malignancy, severe infection or sepsis.\n* Patients with major bleeding.",{"count":132,"type":22},"Cardiovascular diseases remain the primary leading cause of death in patients on maintenance hemodialysis accounting for nearly 41% of deaths.\n\nChronic kidney disease is associated with an excess of acquired arrhythmia of multiple types, and atrial fibrillation in particular.\n\nSudden cardiac death is also more common in chronic kidney disease and accounts for around one- quarter of deaths in dialysis patients.\n\nThe aim of the study is to evaluate the incidence, describe the patterns of cardiac arrhythmia and to determine the factors predisposing to cardiac arrhythmia in patients with chronic kidney disease with or without hemodialysis.",[325],"Chronic Kidney Disease With and Without Hemodialysis",[327,328,329],"chronic kidney disease (CKD)","cardiac arrhythmia","atrial fibrillation (AF)",{"date":331,"type":33},"2026-06-11",{"date":333,"type":22},"2026-07-20",{"date":335,"type":22},"2027-01-20",{"name":39,"class":40},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":345,"conditions":346,"keywords":349,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":41},"100643768","acute-kidney-injury-in-upper-gi-bleeding-patients-100643768","NCT07636083","Acute Kidney Injury in Upper GI Bleeding Patients","Acute Kidney Injury Following Upper Gastrointestinal Bleeding: Incidence and Predictors","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients presenting with clinical features suggestive of acute upper gastrointestinal bleeding (UGIB), including hematemesis, coffee-ground vomiting, or melena\n* Diagnosis of UGIB confirmed by upper gastrointestinal endoscopy or strong clinical evidence when endoscopy is not immediately available\n* Patients admitted to Sohag University Hospitals (medical wards or intensive care unit)\n* Availability of renal function data, including at least one serum creatinine measurement at admission and serial measurements during hospitalization\n* Availability of baseline renal function (previous serum creatinine within 3-12 months) or estimable baseline during hospitalization\n\nExclusion Criteria:\n\n* Patients with end-stage renal disease (ESRD) on chronic dialysis\n* Patients with a history of renal transplantation\n* Patients with advanced chronic kidney disease stage 5 (eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²) not on dialysis\n* Patients with lower gastrointestinal bleeding\n* Patients with incomplete or missing essential renal function data\n* Patients discharged or deceased within 24 hours of hospital admission\n* Pregnant patients\n* Patients with acute kidney injury at presentation due to causes other than UGIB",{"count":132,"type":22},"This study aims to evaluate the incidence of acute kidney injury (AKI) among patients presenting with acute upper gastrointestinal bleeding (UGIB) at Sohag University Hospitals, and to identify predictors associated with renal impairment in these patients.",[347,348],"Upper Gastrointestinal Bleeding","Acute Kidney Injury",[350,351,352,353,354,355,356,357],"UGIB","AKI","Renal Impairment","Gastrointestinal Hemorrhage","Serum Creatinine","Kidney Function","Variceal Bleeding","Non-variceal Bleeding","2026-06-04",{"date":271,"type":33},{"date":361,"type":22},"2026-05-15",{"date":363,"type":22},"2027-05-15",{"name":39,"class":40},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":50,"sex":17,"minAge":19,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":41},"100643200","phase-4-lumbar-erector-spinae-plane-block-versus-fascia-iliaca-plane-block-in-hip-surgeries-as-postoperative-analgesia-100643200","NCT07631416","Lumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia","Inclusion Criteria:\n\n* • Age between ≥ 18 years\n\n  * Both sexes.\n  * American Society of Anesthesiologists (ASA) Physical Status I-III\n  * Undergoing elective unilateral hip surgeries under spinal anesthesia\n  * Patients with body mass index (BMI) \\\u003C 35 kg\u002Fm²\n\nExclusion Criteria:\n\n* • Patient refusal\n\n  * Known allergy to local anesthetics\n  * Infection at the site of block\n  * Coagulopathy or bleeding disorders\n  * Cognitive impairment affecting pain assessment\n  * Chronic opioid use\n  * Neuromuscular disorders as patients with stroke.","90 Years",{"count":132,"type":22},[155],"Lumbar Erector Spinae Plane Block Versus Fascia Iliaca Plane Block in Hip Surgeries as Postoperative Analgesia The aim of this study is to compare the analgesic efficacy of lumbar ElectroSpine Plane Block and Fascia Iliaca Plane Block in patients undergoing hip surgery under spinal anesthesia.",[376],"Post op Pain in Hip Surgeries",[378],"post op pain in hip surgeries",{"date":290,"type":33},{"date":381,"type":22},"2026-05-20",{"date":383,"type":22},"2026-11-28",{"name":39,"class":40},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":393,"enrollmentInfo":394,"targetDuration":395,"studyType":55,"phases":4,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100639263","comparison-of-the-big-score-and-the-pediatric-trauma-score-100639263","NCT07624955","Comparison of the BIG Score and the Pediatric Trauma Score","Comparison of the BIG Score and the Pediatric Trauma Score in Predicting Mortality Among Pediatric Trauma Patients.","BIG|PTS","Inclusion Criteria:\n\n* Pediatric trauma patients from birth up to 16 years of age.\n* Presentation to the Emergency Department within 24 hours of the primary injury.\n\nExclusion Criteria:\n\n* Patients with minor traumas who are treated and discharged directly from the ED.\n* Patients initially managed at and referred from another hospital.\n* Patients whose legal guardians discharge them against medical advice (AMA) before outcome data can be ascertained.","16 Years",{"count":54,"type":22},"1 Month","The goal of this observational study is to evaluate and compare the predictive performance of the BIG Score and the Pediatric Trauma Score (PTS) in predicting mortality among pediatric trauma patients presenting to the emergency department.\n\nThe main questions it aims to answer are:\n\nDoes the BIG Score accurately predict mortality in pediatric trauma patients?\n\nIs the Pediatric Trauma Score (PTS) effective in predicting mortality among pediatric trauma patients?\n\nWhich scoring system demonstrates better sensitivity, specificity, and overall predictive accuracy for mortality?\n\nResearchers will compare the BIG Score with the Pediatric Trauma Score to determine which scoring system provides superior prognostic value in pediatric trauma cases.\n\nParticipants will:\n\nUndergo routine clinical assessment upon admission to the emergency department.\n\nHave vital signs, Glasgow Coma Scale (GCS), and trauma-related clinical parameters recorded.\n\nUndergo laboratory investigations including Base Deficit and International Normalized Ratio (INR).\n\nBe followed during hospitalization to assess outcomes, including survival or mortality.",[398],"Pediatric Trauma Patients",[389],"2026-05-30",{"date":402,"type":33},"2026-06-03",{"date":94,"type":22},{"date":405,"type":22},"2027-02-10",{"name":39,"class":40},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":427,"locationsCount":41},"100637715","association-between-overt-and-sub-clinical-primary-hypothyroidism-and-metabolic-dysfunction-associated-steatoic-liver-disease-in-non-diabetic-patients-100637715","NCT07603817","Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease in Non-Diabetic Patients","Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease (MASLD) in Non-Diabetic Patients","Inclusion Criteria:\n\n* Patients aged ≥18years old who will be:\n* Diagnosed with primary hypothyroidism (overt or sub clinical hypothyroidism) within 3 months with or without levothyroxine treatment.\n* Patients with positive antibody (positive TPO antibody or positive Thyroglobin antibody) irrespective of thyroid status\n* Metabolic dysfunction-associated steatotic liver disease (MASLD) assessment by ultrasound and Fibro-scan.\n\nExclusion Criteria:\n\n* Diabetic patients according to American Diabetes Association (ADA) Criteria.\n* Excessive Alcohol consumption (\\> 30 gm\u002F day in men, 20 gm \u002Fday in women.\n* Body mass index (BMI) index \\>40 kg\u002Fm2\n* Other causes of chronic hepatic steatosis \\[e.g., positive hepatitis B virus (HBV), positive hepatitis C virus (HCV)), autoimmune disease, Wilson disease, drugs\\].\n* Patients use of drugs known to cause hepatic steatosis (e.g., amiodarone, valproate, tamoxifen, methotrexate, steroids).\n* Treatment with drugs that influence liver fat, as thiazolidinediones, α-glucosidase inhibitors, sodium-glucose -transporter 2 (SGLT2) inhibitors or any glucagon-like peptide-1 receptor agonists during the previous 3 months.\n* Detection of biliary duct obstruction based on imaging studies.\n* Evidence of cirrhosis \\[on basis of ultrasonography and magnetic resonance imaging (MRI )\\] or hepatocellular carcinoma \\[evidence on triphasic Computed Tomography (CT) or MRI\\].\n* Presence of any systemic disease that commonly cause liver disease.\n* Severe hepatic injury and\u002For significant abnormal liver function defined as aspartate aminotransferase \\>5× upper limit of normal (ULN) and\u002For alanine aminotransferase \\>5× ULN or elevated total bilirubin \\> 2 mg\u002Fdl.\n* Pregnant women.\n* Patients with active malignancy.\n* History of bariatric surgery or ongoing weight-loss diet (hypocaloric diet) or use of weight-loss agents unless the diet or treatment has been stopped at least 3 months before screening and that the patient has had a stable body weight (+\u002F- 3 kg) during the 3 months before screening.",{"count":132,"type":22},"This study aims to estimate the prevalence of Metabolic dysfunction - associated Steatoic liver disease (MASLD) among adults with primary hypothyroidism (overt or sub-clinical 1ry hypothyroidism) and prevalence of MASLD in Hashimoto-thyroiditis vs Euthyroid controls in non-diabetic patients.",[417,418,419,420,421],"Overt","Sub-clinical","Primary Hypothyroidism","Metabolic Dysfunction-Associated Steatoic Liver Disease","Non-Diabetic Patients",{"date":423,"type":33},"2026-06-02",{"date":425,"type":33},"2026-03-01",{"date":294,"type":22},{"name":39,"class":40},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":23,"phases":437,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":448,"locationsCount":41},"100639205","outcomes-of-laparoscopic-keyhole-surgery-tapp-for-recurrent-inguinal-hernia-100639205","NCT07608653","Outcomes of Laparoscopic Keyhole Surgery (TAPP) for Recurrent Inguinal Hernia","Clinical Outcomes of Laparoscopic Transabdominal Preperitoneal (TAPP) Approach for Recurrent Inguinal Hernia","Inclusion Criteria:\n\n* Adult patients. Patients diagnosed with recurrent inguinal hernia. Patients fit for general anesthesia. Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Non recurrent inguinal hernia Patients with complicated inguinal hernia. Patients unfit for general anesthesia. Patients refusing participation in the study.",{"count":436,"type":22},10,[25],"The goal of this clinical trial is to learn if a laparoscopic surgery called Transabdominal Preperitoneal (TAPP) repair is safe and works well for adults with a recurrent inguinal hernia (a groin hernia that has returned after a previous operation).\n\nThe main questions it aims to answer are:\n\nDoes the TAPP technique lower the number of complications after surgery? How well do participants recover during the early postoperative period and long-term follow-up? Fixing a hernia that has returned is hard because of old scar tissue. In this study, researchers will use the TAPP technique to work through a different layer of tissue to provide a stronger repair.\n\nParticipants will:\n\nUndergo the TAPP laparoscopic surgery for their recurrent hernia. Visit the clinic for close health monitoring shortly after surgery. Complete regular follow-up checkups to track their long-term recovery.",[440],"Recurrant Inguinal Hernia",[442,443],"Tapp repair","Recurrant inguinal hernia","2026-05-27",{"date":249,"type":33},{"date":206,"type":33},{"date":116,"type":22},{"name":39,"class":40},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":50,"sex":17,"minAge":19,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100640359","internet-addiction-and-sleep-quality-among-medical-students-100640359","NCT07609784","Internet Addiction and Sleep Quality Among Medical Students","Impact of Internet Addiction on Sleep Quality and Academic Performance Among Medical Students at Sohag University.","Inclusion Criteria:\n\n* Medical students in Sohag university\n* Students who agree to participate in the study.\n\nExclusion Criteria:\n\n* • Students with known psychiatric illness (e.g., major depressive disorder, schizophrenia).\n\n  * Students with diagnosed neurological disorders or primary sleep disorders (e.g., epilepsy, narcolepsy, obstructive sleep apnea).\n  * Students who decline participation.","25 Years",{"count":458,"type":22},499,"Internet addiction has become increasingly prevalent among medical students and may negatively affect sleep quality and academic performance. This cross-sectional study aims to assess the prevalence of internet addiction among medical students at Sohag University and evaluate its relationship with sleep quality and academic achievement using validated assessment tools.",[461,462,463,464],"Internet Addiction Level","Quality of Sleep","Medical Students","Academic Performance","2026-05-26",{"date":444,"type":33},{"date":468,"type":22},"2026-07",{"date":470,"type":22},"2027-06",{"name":39,"class":40},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":50,"sex":17,"minAge":480,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":484,"conditions":485,"keywords":488,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":493,"leadSponsor":495,"locationsCount":4},"100640356","health-anxiety-and-quality-of-life-among-faculty-of-medicine-students-100640356","NCT07608185","Health Anxiety and Quality of Life Among Faculty of Medicine Students","Impact Of Health Anxiety On Quality Of Life Among Students Of Faculty Of Medicine At Sohag University","HAQoL-FMSU","Inclusion Criteria:\n\n* Medical students currently enrolled at Sohag University Faculty of Medicine\n* Both genders\n* provide informed consent\n\nExclusion Criteria:\n\n* Students who diagnosed with severe psychiatric disorders\n* Students currently receiving psychiatric treatment that may affect anxiety levels\n* Incomplete questionnaires\n* Students who refuse to participate","20 Years","23 Years",{"count":483,"type":22},400,"This cross-sectional analytical study aims to assess the impact of health anxiety on quality of life (QoL) among medical students at the Faculty of Medicine, Sohag University, Egypt. Health anxiety will be measured using the Short Health Anxiety Inventory (SHAI), and quality of life will be assessed using the Short Form-12 Health Survey (SF-12), covering both Physical Component Summary (PCS) and Mental Component Summary (MCS). The study targets third-year (pre-clinical) and fifth-year (clinical) students selected by cluster sampling. Findings will help identify prevalence and determinants of health anxiety and its impact on QoL, informing mental health support strategies for medical students in Upper Egypt.",[486,487],"Health Anxiety","Quality of Life",[486,487,463,489,490],"SF-12","SHAI",{"date":444,"type":33},{"date":116,"type":22},{"date":494,"type":22},"2026-10-30",{"name":39,"class":40},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":104,"minAge":4,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":41},"100638364","accuracy-of-transabdominal-ultrasound-in-predicting-intraperitoneal-adhesions-prior-to-laparoscopy-100638364","NCT07605533","Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy","Inclusion Criteria:\n\n* Women scheduled for elective laparoscopy.\n* Women with history of previous laparotomies.\n* Women with previous transverse suprapubic and\u002For any midline incision.\n* Women with previous caesarean section.\n\nExclusion Criteria:\n\n* Women with Emergency laparoscopic surgeries (e.g., acute abdomen).\n* Pregnancy at time of operation.\n* Morbid obesity (BMI \\> 40kg\u002Fm²), as excessive adipose tissue may limit ultrasound imaging.\n* Severe medical conditions affecting participation (e.g., severe cardiac or pulmonary disease.",{"count":503,"type":22},74,"Detecting Accuracy of transabdominal ultrasound in detecting intraperitoneal adhesions prior to laparoscopy ( which is the gold standard to visualize adhesions ) to detect safety of 1ry trocar insertion .",[506],"Intraperitoneal Adhesions",[508],"intraperitoneal adhesions",{"date":465,"type":33},{"date":511,"type":33},"2025-05-01",{"date":65,"type":22},{"name":39,"class":40},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":50,"sex":17,"minAge":521,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":4},"100641035","phase-4-dexmedetomidine-vs-propofol-lidocaine-mixture-in-preventing-the-post-operative-emergence-agitation-following-sevoflurane-anasthesia-100641035","NCT07601698","Dexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia","The Efficacy of Dexmedetomidine Versus Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anesthesia in Pediatric Ophthalmic Surgeries , A Prospective Randomized Comparative Controlled Study","Inclusion Criteria:\n\n* patients aged 2-8 years .\n* ASA physical status I-II.\n* Scheduled for elective surgeries under general anesthesia with sevoflurane\n\nExclusion Criteria:\n\n* History of psychiatric illness or cognitive impairment.\n* Known allergy to study drugs.\n* Severe cardiovascular, hepatic, or renal disease.\n* Chronic use of sedatives or opioids.","2 Years","8 Years",{"count":132,"type":22},[155],"Primary we will Compare the Efficacy between Dexmedetomidine and \"Propofol-lidocaine\" mixture in preventing the post operative emergence agitation following sevoflurane anasthesia in pediatric ophthalmic surgeries Secondary we will evaluate time of extubation, time of orientation, Hemodynamic variables, Visual analog scale ( VAS), facial expressions scale , Adverse events",[527],"Emergence Agitation",[529],"EA","2026-05-19",{"date":165,"type":33},{"date":533,"type":22},"2026-05-01",{"date":535,"type":22},"2026-12",{"name":39,"class":40},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":480,"maxAge":150,"enrollmentInfo":544,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":41},"100639522","rlb-vs-ersp-for-postoperative-analgesia-in-lap-cholecystectomy-100639522","NCT07598162","RLB vs ERSP for Postoperative Analgesia in Lap Cholecystectomy","Retrolaminar Block Versus Erector Spinae Plane Block for Postoperative Analgesia in Laparoscopic Cholecystectomy: A Comparative Randomized Prospective Study","Inclusion Criteria:\n\n* • Age from 20 to 60 years.\n\n  * Both sexes.\n  * American Society of Anesthesiology (ASA) grade I and II physical status.\n  * Patients will undergo cholecystectomy under general anesthesia.\n\nExclusion Criteria:\n\n* • Sensitivities or contraindications to the study medications.\n\n  * Infection at the site of injection.\n  * Emergency surgery.\n  * Body mass index (BMI) \\> 35.\n  * Organic comorbidities.\n  * Histories of psychological conditions and\u002For chronic pain syndromes.\n  * Contraindications to regional anesthesia.\n  * Severe respiratory, cardiac, hepatic and renal disorders.\n  * Pregnancy.\n  * Coagulopathy.\n  * Opioid addiction.",{"count":176,"type":22},[25],"This prospective, randomized, double-blind clinical trial evaluates the comparative effectiveness of ultrasound-guided retrolaminar block (RLB) and erector spinae plane block (ESPB) for postoperative analgesia in patients undergoing laparoscopic cholecystectomy. A total of 100 ASA I-II patients, aged 20-60 years, will be randomly allocated into two equal groups to receive either RLB or ESPB bilaterally following induction of standardized general anesthesia. The primary outcome is the time to first request for rescue analgesia, while secondary outcomes include total morphine consumption within the first 24 hours, postoperative pain scores assessed using the Numeric Rating Scale (NRS), patient satisfaction, and the incidence of adverse events. Pain assessment will be performed at predefined intervals over the first 24 hours postoperatively. The study aims to determine which technique provides superior analgesia with reduced opioid requirements and improved patient outcomes.",[548],"Laparoscopic Cholecystectomy Surgery Postoperative Analgesia","2026-05-18",{"date":381,"type":33},{"date":552,"type":22},"2026-04",{"date":554,"type":22},"2027-09-01",{"name":39,"class":40},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":393,"maxAge":150,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":571,"leadSponsor":573,"locationsCount":41},"100640599","polidocanol-1-and-steroid-in-keloids-and-hypertrophic-scars-100640599","NCT07606391","Polidocanol 1% and Steroid in Keloids and Hypertrophic Scars","Efficacy and Safety of Intralesional Injection of Polidocanol 1% in Treatment of Keloids and Hypertrophic Scars","Inclusion Criteria:\n\n\\- Patients older than 16 years of both sex with keloids and\u002For hypertrophic scars ≤ year.\n\nExclusion Criteria:\n\n1. Pregnancy, lactation.\n2. Skin lesions, infection in the injection area.\n3. Patients with systemic disease (diabetes mellitus, heart disease, cancer, mental illness).\n4. Allergy to substances used.\n5. Patients received treatment in previous 4 weeks.\n6. Current anticoagulant therapy.\n7. Active thromboembolic disease, use of oral contraceptives or other drugs affecting coagulation cascade.\n8. History of venous or arterial thromboembolism.\n9. Severe renal dysfunction.",{"count":564,"type":22},90,[25],"we will inject intralesional polidocanol 1% in keloids and hypertrophic scars to decrease vascularity and decrease size of lesion compared to intralesional steroid as standard treatment line",[568],"Keloid and Hypertrophic Scars",{"date":465,"type":33},{"date":65,"type":22},{"date":572,"type":22},"2027-08-01",{"name":39,"class":40},""]